Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 14;11(3):e006292. doi: 10.1136/jitc-2022-006292

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

UB-VV100 treatment results in in vivo transduction of CAR T cells and clearance of Nalm-6 tumor. (A) Animals were engrafted with Nalm-6 tumor on study day −4 via tail vein injection, humanized with 20E+06 PBMCs on day −1 via intraperitoneal injection, and treated with 27 million, 80 million or 270 million TU of UB-VV100 on study day 0 via intraperitoneal injection. (B) T-cell activation was assessed on day 4 by flow cytometry. **P<0.01, ****P<0.0001, one-way ANOVA, Tukey’s multiple comparison test between the indicated groups. (C) Circulating CAR T cells were enumerated by flow cytometry surface staining against FMC63. ***P<0.001, one-way ANOVA for day 11. n=7–9 per group per time point. (D) Animal survival was evaluated during the study. (E) Average tumor burden as assessed by bioluminescent imaging. (F) Heatmap of bioluminescent imaging data overlayed with mouse images. The last observed in-life photon flux data were reported for deceased animals at the indicated time points. **P<0.01, ****P<0.0001, two-way ANOVA, multiple comparisons between the indicated UB-VV100 dose level across the entire observation period. n=7–9 per group, ****P<0.0001, Mantel-Cox test. ANOVA, analysis of variance; CAR, chimeric antigen receptor; IVIS, In Vivo Imaging System; PBMC, peripheral blood mononuclear cell; TU, transducing unit.